Mr Adar Poonawalla, Chief Executive Officer, Serum Institute of India explained how the Institute had to raise export and capacity, and also empower the team, to be able to produce vaccines on such a large scale. He also emphasized how capacity and resilience have to be built to ensure India’s health security at AIMA’s National Leadership Conclave 2022.
Mr Adar Poonawalla, Chief Executive Officer, Serum Institute of India addressed the audience from the panel in one of AIMA’s National Leadership Conclave sessions on how strong measures have to be taken to build capacity and resilience in the health care supply chain to ensure India’s health security under all circumstances, in addition to narrating the journey of how his company produced vaccines during the pandemic.
Mr Poonawala started the session by ruminating on how Serum worked on the export and raised the capacity, and also empowered the team to be able to do things ahead of time, which only became the reasons for the Institute to be able to produce vaccines that exceeding expectations, during the commencement of the covid pandemic.
He explained how he took the decision of producing the vaccines by partnering with renowned universities and academia, investing the company’s own money in it, raising capital from other countries, and building capacity, even though being in a legacy business, which is why the company was able to produce vaccines in bulks.